Home | Medical-Newswire.Com:
(EMAILWIRE.COM, March 21, 2012 ) New York, NY -- NovaBay Pharmaceuticals (NBY) released news this week that offers to broaden the scope and reach of the company's Aganocide compounds, which are being positioned as anti-infectives and could potentially replace modern day antibiotics as resistance to such treatment grows.
On Tuesday NovaBay announced a deal with Virbac Animal Health to bring its technology to the veterinary market. According to the agreement, NovaBay will receive an upfront payment - and some additional support for research and development - while Virbac will retain the option to license any of the Aganocide compounds that are successfully applied to treating veterinary indications.
The deal could provide NovaBay with a steady revenue stream in the future if Virbac exercises its licensing option. According to the Tuesday press release, if the option is exercised,
"NovaBay may receive additional payments, which include an exercise fee as well as development and pre-commercial milestones for a line of veterinary products. NovaBay will also receive royalties on sales of any successfully commercialized Aganocide products to arise from this agreement."
Few companies are going to become superpowers in the field of medicine on treating veterinary indications alone, but the deal brings some attention back to NovaBay and gives us another chance to consider this company's technology on the open market - should the pipeline products make it that far.
It also gives us the opportunity to determine whether or not the current market capitalization for NBY justifies that pipeline potential, which, in the opinion of this writer, the determination is "probably not."
First, let's revisit the problem of antibiotic resistance.
When introduced into society seventy years ago, antibiotics changed the shape of medicine, and provided what - at the time - was considered a huge leap forward in treating bacterial infections. Having been so widely-used since then, however, the infectious organisms against which the antibiotics are administered have grown increasingly resistant, and sometimes immune, to today's antibiotic treatments.
The Centers for Disease Control and Prevention considers the developing resistance to antibiotics as a "crisis", noting on its website that, "These drugs have been used so widely and for so long that the infectious organisms the antibiotics are designed to kill have adapted to them, making the drugs less effective. People infected with antimicrobial-resistant organisms are more likely to have longer, more expensive hospital stays, and may be more likely to die as a result of the infection."
Medical professionals themselves understand the growing risks associated with antibiotic resistance, as noted by Dr. Marc Siegel, associate professor of medicine and medical director of Doctor Radio at NYU Langone Medical Center, this week in an article published on FoxNews.com. Dr. Siegel also notes that Doctors continue to over prescribe these treatments, thereby strengthening the resistance of the surviving bacteria and creating new "super colonies" that will eventually be uncontrollable.
This dilemma has created a huge monetary burden on the global health care system and is possibly setting up a one-time "miracle cure" as irrelevant.
That's where NovaBay comes into the picture.
NovaBay has developed, through its proprietary Aganocide compounds, a pipeline of synthetic anti-infectives that are designed to mimic the body's own defenses against infection. Namely, these synthetic molecules, based on the Aganocide compound NVC-422, essentially act in the same manner and processes of a body's white blood cells and not as antibiotics, therefore significantly reducing the risk of a resistance being developed.
The potential of such a technology has market-moving implications, and under the circumstances, it's understandable why NBY could be tagged with an 'undervalued' label.
There are, however, a couple of reasons why investors may not yet have fully embraced the company and its technology. The first reason may be the most obvious one; that NovaBay still has nothing beyond Phase II, and therefore any investment in the company is highly speculative and risky at this point, which is a fair assessment.
That said, the best deals in biotech are the ones that are found early, when patience is needed as the trial results pan out. It's also worth noting, however, that he trend of staying away from speculative "Phase II" investments may be shifting.
Take Lpath, Inc. (LPTN), for example. Lpath also has a novel and potentially groundbreaking technology in the works, but Pfizer (PFI) has bucked the Phase II label of the company and jumped in with a very significant partnership.
CellDex Therapeutics (CLDX) is another one that has traded very highly during its Phase II stages, even when Pfizer decided to divorce itself from a partnership with the company.
In both cases, investors may have started to become clued in to how much market potential is contained within those respective pipelines and tossed the standard "wait until Phase III" strategy to the side. As investors with similar strategies in mind research NovaBay, the same potential for price appreciation exists; especially give the fact that NBY has a powerhouse partner of its own in Galderma SA, with whom NovaBay is developing a treatment for the highly-contagious skin condition, Impetigo.
Another reason why NovaBay may be missing the mark in terms of market cap right now, and this one may be more relevant than the last, is that an earlier clinical trial conducted with then-partner Alcon in the treatment of adenoviral conjunctivits - better known to the average Joe as "pink eye" - failed.
Shares slumped badly after that news hit the presses and have only barely recovered since.
On the flip side to the endpoint miss, however, which sent sent investors running for the doors, is that a further look at the data from the same trial did show that efficacy was demonstrated against Epidemic Keratoconjunctivitis (EKC), possibly the most contagious form of the infection, and which often threatens a victim's vision.
Based on that data, trials have continued, but the fact that the company has a failed trial under its belt most certainly deters some investors from jumping back in, at least until they see more results.
A Phase IIb trial for this indication is expected to begin within months, while another Phase II trial for the Impetigo condition is also slated for this year.
Results from 'Part A' from a trial testing NVC-422 as a treatment for urinary catheter blockage and encrustation (UCBE) have already rolled in, with results from 'Part B' also due within months.
The pending trial results provide some short term catalysts, but another catalyst due for this year could be the one that puts NovaBay on the map.
A commercial launch is planned for the short to mid term for NeutroPhase, NBY's first FDA-cleared product and a treatment for chronic wound in both hospital and personal care. A successful launch for NeutroPhase could alleviate many of the monetary concerns normally associated with a small company bringing its pipeline through trials, and just a couple of months ago the company announced its first strategic partner for NeutroPhase.
Having a product already on the market and bringing in revenue will go a long way to validating this small company in the eyes of potential investors, especially if the NeutroPhase commercial launch goes off without a hitch.
Based on the pending trial catalysts, the commercial launch of NeutroPhase, and most importantly, the potential of NVC-422 products on the open market as eventual substitutes for antibiotics, NBY may still be trading under the radar and could still be lightly valued, when all is considered.
By 2013 the NovaBay could have three Phase III trials ongoing with an FDA approved product on the market.
If that's the case, it's a fair bet to assume that the market cap will be significantly higher than thirty five million at that point.
For an example of how a shift from Phase II to Phase III can effect a market cap, one could look at Keryx BioPharmaceuticals (KERX). During the early to mid stages of Phase II, the KERX market cap was similar to NBY's now, but when Phase II trials were successful and Phase III came along?
Prices quickly quadrupled.
NovaBay's target market of anti-infective care is a multi-multi-billion dollar market annually, and NBY could quickly penetrate that market, as Doctors are currently looking for a way around antibiotic resistance.
As I've previously discussed, this company may be at the right place at the right time. For investors being in the right place at the right time means being "in" before any price run starts, and it's possible that NBY has a ways to move, should the pending catalysts turn out positive.
Disclosure: Long NBY.
For more information and commentary regading NBY, visit: http://vfcsstockhouse.com/blog/article/-novabay-may-be-in-the-right-place-at-the-right-time-with-an-answer-for-antibiotic-resistance
Contact VFC's Stock House: email@example.com
VFC's Stock House offers research-based investment information, insights and ideas on a variety of different companies in numerous sectors, with a focus on biotech stocks and healthcare.
For full reports on Celsius Holdings and other companies visit: http://vfcsstockhouse.com
Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse
'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213
For full disclaimer visit: http://vfcsstockhouse.com
VFC's Stock House
Health News Headlines - Yahoo News
Get the latest health news headlines from Yahoo News. Find breaking health news, including analysis and opinion on
top health stories.
Doctors puzzle over severity of defects in some Brazilian babies
7 Feb 2016 at 6:57am
By Bill Berkrot and Anthony Boadle NEW YORK/BRASILIA (Reuters) - Experts on microcephaly, the birth defect that has sparked alarm in the current Zika virus outbreak, say they are struck by the severity of a small number of cases they have reviewed from Brazil. Consultations among doctors in Brazil and the United States have increased in the last two weeks, and some of the leading authorities on the condition are finding patterns of unusual devastation in scans of the newborns' malformed brains. While it's not known how representative the scans are, the early observations of these doctors point to a tough road ahead for the babies, their families and their communities and heighten the concern surrounding Zika, which is suspected of causing microcephaly.
France restricts blood transfusions over Zika virus
7 Feb 2016 at 6:08am
Travelers coming back from any outbreak zones of the Zika virus will need to wait at least 28 days before giving blood to avoid any risk of transmission, French Health Minister Marisol Touraine said on Sunday. Zika, which is rapidly spreading through the Americas and has been declared a global health emergency by the World Health Organisation (WHO), is primarily transmitted through mosquito bites. "Someone who comes from a zone where there is Zika can not give blood for 28 days," Touraine said in an interview with Europe 1 radio, news channel iTele and Le Monday daily.
Rio carnival goers tell Zika mosquito to buzz off
7 Feb 2016 at 6:01am
A massive, fleshy crowd of semi-naked people might seem like the Zika-transmitting mosquito's paradise, but Rio Carnival goers Saturday said nothing -- not even an international health emergency -- can stop the party. The peak weekend of Rio de Janeiro's Carnival season got underway with an estimated one million people cramming into the city center for the Cordao da Bola Preta street party.
Bootleg liquor kills at least 24 in Indonesian village: media
7 Feb 2016 at 5:19am
Bootleg liquor has killed at least two dozen people in a village in Indonesia's Central Java province over the last few days, MetroTV said on Sunday quoting police. Police have arrested two people in the village of Sleman for selling homemade liquor that was believed to have contained harmful substances. "Police have sent the hard liquors mixed with harmful substances to the laboratory in Semarang to be tested," MetroTV quoted Sleman police chief Yulianto as saying.
Exclusive: Zika virus discourages many Americans from Latin America travel
7 Feb 2016 at 5:15am
The rapidly spreading Zika virus is discouraging many Americans from traveling to Latin America and the Caribbean, with 41 percent of those aware of the disease saying they are less likely to take such a trip, a Reuters/Ipsos poll shows. Airlines and cruise ship operators have yet to report drops in bookings because of Zika, and analysts have downplayed the impact that newly sedentary parents-to-be could have on their revenue. "I am actively trying to get pregnant with my husband, so I am a little bit concerned," said Erica, a respondent who said she was bitten by a mosquito during a January trip to the U.S. Virgin Islands, where Zika has been reported.
Loan rejection may have been early warning of Taiwan building collapse
7 Feb 2016 at 5:02am
By Yimou Lee TAINAN, Taiwan (Reuters) - Before their apartment tower collapsed in a Taiwan earthquake at the weekend, a young couple living on the 14th floor had already been given a clue that the building was unsafe. Chen Yi-ting and her husband bought the apartment in the center of Tainan city five years ago, having relocated from an outlying district.
Duchess of Cambridge: Support children's mental health
7 Feb 2016 at 4:24am
LONDON (AP) ? The Duchess of Cambridge says in a new video that she and Prince William want all children to get support during difficult times to help them overcome mental health challenges.
Cricket-Pakistan's Shah banned for three months for doping offence
7 Feb 2016 at 3:58am
Pakistan leg-spinner Yasir Shah has been given a three-month ban after pleading guilty to an inadvertent doping offence, the International Cricket Council said on Sunday. Chlortalidone is a diuretic drug which features in the World Anti-Doping Agency's (WADA) list of prohibited substances. Shah pleaded guilty to the charge and said he had mistakenly taken his wife's blood pressure medication which contained the banned substance.
Athletes weigh gold lust against Zika health fears
7 Feb 2016 at 3:46am
By Ossian Shine and Joshua Schneyer LONDON/NEW YORK (Reuters) - As global health chiefs try to bring a Zika virus epidemic under control, aspiring Olympic athletes are weighing their lust for gold against health fears surrounding the mosquito-borne virus in Brazil. Alarm has grown since the World Health Organization (WHO) on Monday declared Zika an international health emergency that could infect as many as 4 million people in the Americas. Zika is carried by mosquitoes, which transmit the virus to humans, while two cases in the United States suggest it may also be transmitted sexually.
Australia pledges aid to help Tonga, Pacific with Zika
7 Feb 2016 at 1:53am
By Morag MacKinnon PERTH (Reuters) - Australia pledged up to A$500,000 ($354,000) in aid for its Pacific island neighbors on Sunday to help combat the spread of the Zika virus after an outbreak in Tonga last week raised concern in the region. The initial focus on strengthening the fight against the mosquito-borne virus would be in Tonga, Steven Ciobo, minister for the Pacific, said in a statement. Australia would work with World Health Organization (WHO) officials and the Tongan government to control the mosquito population and increase access to testing, he said.
Despite treatment advances, AIDS stigma lingers in rural South Africa
7 Feb 2016 at 1:45am
By Laurie Goering QUDENI, South Africa (Thomson Reuters Foundation) - When Eunice Khanyile opened a soup kitchen in a rural village in South Africa last year to help HIV-positive residents get the nutrition needed to stay healthy, not one person came. When it comes to AIDS, "the stigma is a huge problem", she said. People do not want to open up to others about their status." Today, just over 200 people eat the lunch cooked daily at the yellow-painted cement block kitchen in Qudeni, drawn by the smell of butternut and lentils and the banging of pots and pans.
Fear of cholera, floods as Burundi refugees pack Tanzania camps
7 Feb 2016 at 1:30am
By Katy Migiro NAIROBI (Thomson Reuters Foundation) - Heavy rains, flooding and a spike in new arrivals could threaten the lives of over 110,000 Burundian refugees in overcrowded camps in Tanzania, six aid agencies said on Monday, amid warnings of rising political tension in Burundi. Life-threatening malaria and diarrhoea have been spreading in Nyarugusu, the world's third largest refugee camp, since the rainy season began, and damage caused by a powerful El Nino has left aid agencies short of funds throughout east Africa. "Refugees are arriving in their hundreds every day," the agencies, which include Oxfam, Save the Children and HelpAge International, said in a statement.
Republican U.S. presidential hopefuls say Zika quarantine may be needed
6 Feb 2016 at 9:04pm
Two Republican U.S. presidential hopefuls said on Saturday they would implement quarantines of travelers if necessary to stop the spread of the Zika virus. New Jersey Governor Chris Christie, who garnered international attention in 2014 when he quarantined a nurse who returned to the United States after treating Ebola patients, said he would not hesitate to do it again. "You bet I would," Christie said during a debate in New Hampshire with other Republican contenders for the White House.
Mormon church comes out against Utah medical marijuana bill
6 Feb 2016 at 8:21pm
SALT LAKE CITY (AP) ? The Mormon church has come out against a Utah bill that would allow the medical use of edible pot products, a position that could be a serious blow to one of two medical marijuana proposals before state lawmakers.
More than 3,100 pregnant women in Colombia have Zika virus: government
6 Feb 2016 at 7:46pm
By Julia Symmes Cobb BOGOTA (Reuters) - More than 3,100 pregnant Colombian women are infected with the mosquito-borne Zika virus, President Juan Manuel Santos said on Saturday, as the disease continues its rapid spread across the Americas. Brazil is investigating the potential link between Zika infections and more than 4,000 suspected cases of microcephaly, a birth defect marked by an abnormally small head size that can result in developmental problems. Researchers have identified evidence of Zika infection in 17 of these cases, either in the baby or in the mother, but have not confirmed that Zika can cause microcephaly.